Description:
Cannabis policies are constantly changing. Massachusetts has had medical and recreational laws in place for many years now. As a result, many of our patients are either interested in using cannabis or cannabinoids or are already doing so. Clinicians need to know the latest cannabis science in order to talk about cannabis with their patients in a sensible, evidence-based manner.
Many people use cannabis or other cannabinoids like CBD to treat a wide array of medical problems. The evidence supports the use of cannabis or cannabinoids for some of these conditions, but for many, it does not. In this seminar, Dr. Hill will review the evidence for both the risks and the benefits of cannabis and cannabinoids like CBD so that healthcare professionals can help patients make more informed choices about using these complex substances.
For a subset of individuals, their cannabis use escalates into a problem in key spheres of their lives like work, school, or relationships. Many of these people don’t seek treatment unfortunately. For those that do, however, we will discuss the treatment of individuals with cannabis use disorder.
This is an introductory program for all mental health professionals.
Learning Objectives:
Describe the epidemiology of cannabis use as policies have changed.
Explain acute and chronic risks of cannabis use.
Discuss current state of the evidence for the therapeutic use of cannabis.
Identify challenges associated with the increasing popularity of cannabidiol.
About the Presenter:
Kevin Hill, MD, MHS is Director of Addiction Psychiatry at Beth Israel Deaconess Medical Center (BIDMC) an Associate Professor of Psychiatry at Harvard Medical School. He earned a Master’s in Health Science at the Robert Wood Johnson Clinical Scholars Program at the Yale School of Medicine. He most commonly treats patients who have problems with alcohol, cannabis, or opioids. The author of Marijuana: The Unbiased Truth about the World’s Most Popular Weed, Dr. Hill’s research interests include the development of medications to treat cannabis use disorder as well as cannabis policy, and he has published widely on these topics in such journals as JAMA, JAMA Internal Medicine, and Lancet Psychiatry. In 2018, he was awarded a grant to summarize the research on the therapeutic use of cannabis and he presented his findings to the World Health Organization’s Expert Committee on Drug Dependence in Geneva, Switzerland in June 2018. He serves on the editorial boards of Lancet Psychiatry, Cannabis and Cannabinoid Research, and American Journal on Addictions.
Location:
Live
September 15, 2023
9:00am to 12:00pm
Credits:
3 CE credits
Cancellation Policy:
Cancellation of your registration with full refund can be done up to 7 days before the event. Please email support@thececompany.com to request your cancellation.
Grievances Policy:
We seek to ensure equitable treatment of every person and to make every attempt to resolve grievances in a fair manner. Please email support@thececompany.com with your written grievance. Grievances would receive, to the best of our ability, corrective action in order to prevent further problems.
ADA Assistance:
This program adheres to the standards of the Americans Disabilities Act. Please contact support@thececompany.com if special accommodation is required.
Conflict of Interest:
There is no known commercial interest or conflict of interest for this program.
The CE Company is approved by the American Psychological Association to sponsor continuing education for psychologists. The CE Company maintains responsibility for this program and its content
